Uncategorized
ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold
Novo Nordisk and Eli Lilly presented data extolling the benefits of their relative weight loss therapies in obesity-linked indications, while analysts at BMO Capital Markets were “encouraged” by the strategy communicated by Novo management.